The class of chemicals known as LPAAT-ζ inhibitors encompasses various compounds that can influence the activity of the lysophosphatidic acid acyltransferase-ζ, an enzyme involved in the biosynthesis of phospholipids by catalyzing the acylation of lysophosphatidic acid (LPA). These inhibitors can exert their effects through several mechanisms, primarily by modulating the cellular pathways that govern lipid metabolism and the availability of substrate required for LPAAT-ζ's enzymatic action. Some of these chemicals work by activating or inhibiting regulatory proteins that indirectly control the expression levels or the enzymatic activity of LPAAT-ζ, while others can alter the availability of necessary substrates or co-factors. The compounds act by engaging with various metabolic and signaling pathways that intersect with the functional role of LPAAT-ζ, effectively leading to changes in the enzyme's activity.
The approach to inhibiting LPAAT-ζ centers on the interconnectivity of metabolic pathways, where changes in one part of cellular metabolism can ripple through and affect other processes. For instance, activating enzymes that regulate energy expenditure and fat oxidation can shift the equilibrium away from lipid synthesis, thereby reducing the demand on LPAAT-ζ's activity. Similarly, compounds that change the expression of genes related to fatty acid and lipid metabolism can alter the levels of enzymes upstream or downstream of LPAAT-ζ, which in turn can modify the enzyme's activity. This class of inhibitors utilizes the inherent flexibility and adaptability of metabolic pathways to adjust the enzymatic landscape in which LPAAT-ζ operates. By targeting different aspects of metabolism, such as fatty acid synthesis, degradation, and storage, as well as overall energy balance, these chemicals can lead to a decrease in the functional throughput of LPAAT-ζ. The efficacy of these inhibitors relies on their ability to integrate into the complex network of metabolic regulation, ensuring that the activity of LPAAT-ζ is modulated in accordance with the altered metabolic state induced by these compounds.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
As a PPARα agonist, fenofibrate can modulate the expression of genes involved in fatty acid oxidation, which could possibly inhibit LPAAT-ζ by diverting fatty acids towards oxidation rather than triglyceride synthesis. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
This PPARγ agonist alters adipogenesis and lipid metabolism, which could possibly inhibit LPAAT-ζ through its effects on adipocyte differentiation and insulin sensitivity. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $43.00 $65.00 $200.00 $815.00 | 6 | |
Nicotinamide, a form of vitamin B3, can act as an inhibitor of sirtuins (like SIRT1), which are involved in regulating metabolism and fat storage, which could possibly inhibit LPAAT-ζ activity or expression. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR is an AMPK activator that can mimic cellular energy depletion, leading to altered lipid metabolism, which could possibly inhibit LPAAT-ζ expression or reduce its substrate availability. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
This PPARγ antagonist could possibly inhibit LPAAT-ζ by influencing its expression through the inhibition of PPARγ, a key regulator in lipid metabolism. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $133.00 | 7 | |
A PPARα agonist that could possibly inhibit LPAAT-ζ by decreasing triglyceride synthesis, upregulating fatty acid oxidation, and indirectly affecting the enzyme's activity. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
A statin that inhibits HMG-CoA reductase, which could possibly inhibit LPAAT-ζ by altering lipid regulatory pathways and cellular lipid content. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Another PPARγ agonist that modulates fatty acid storage and glucose metabolism, which could possibly inhibit LPAAT-ζ through systemic effects on lipid homeostasis. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $90.00 | 1 | |
An alkaloid shown to activate AMPK, which could possibly inhibit LPAAT-ζ by influencing lipid metabolism and reducing lipogenesis enzyme expression or activity. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
By inhibiting HMG-CoA reductase, atorvastatin could possibly inhibit LPAAT-ζ through changes in intracellular lipid signaling and metabolism. | ||||||